Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

84.69 +0.86 (+1.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
AstraZeneca's Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at ESMO. 
Via Investor's Business Daily
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca Reportedly Nears Drug Pricing Deal With President Trump
Via Stocktwits
AstraZeneca Announces $4.5B Investment In Virginia
Via Stocktwits
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
From AstraZeneca
Via Business Wire
Invo Fertility Stock Is Plunging After White House Announcement
INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible. 
Via Benzinga
IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report
UK finance minister Rachel Reeves told reporters that the country needs to be an attractive place for pharma, including in terms of pricing. 
Via Benzinga
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients
Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile. 
Via Benzinga
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial. 
Via The Motley Fool
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes. 
Via Benzinga
AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug
The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 
Via Stocktwits
AstraZeneca unveils expanded manufacturing facility in Texas
From AstraZeneca
Via Business Wire
AstraZeneca PLC (NASDAQ:AZN): A Caviar Cruise Quality Investment
Discover AstraZeneca, a top-quality stock with strong growth, high ROIC, and robust cash flow. A prime candidate for long-term investors seeking durable competitive advantages. 
Via Chartmill
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion. 
Via Benzinga
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to... 
Via MarketMinute
Topics Artificial Intelligence
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
From AstraZeneca
Via Business Wire
Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans
Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing model. 
Via Benzinga
Topics Government
UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments
UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies. 
Via Benzinga
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Economy Intellectual Property Retirement
AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity Drugs
AstraZeneca will invest $4.5 billion in a Virginia facility, creating 3,600 jobs and producing advanced cancer and metabolic medicines using AI and automation. 
Via Benzinga
Topics Artificial Intelligence
Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch
Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers. 
Via Benzinga
Topics Government
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
From AstraZeneca
Via Business Wire
A Look Into AstraZeneca Inc's Price Over Earnings
 
Via Benzinga
Should You Forget Nvidia and Buy These 2 Millionaire-Maker Stocks Instead?
These two up-and-coming tech stocks just might make investors more money over the next decade than Nvidia will. 
Via The Motley Fool
Topics Artificial Intelligence
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension
AstraZeneca's Baxdrostat cut 24-hour systolic blood pressure in a Phase 3 trial, showing promise for treatment-resistant hypertension patients. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.